Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

20.0%

3 terminated out of 15 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (3)
P 1 (2)
P 2 (3)
P 3 (2)

Trial Status

Not Yet Recruiting3
Terminated3
Recruiting3
Completed3
Withdrawn1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT03425526Phase 1Recruiting

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

NCT07391046Not Yet Recruiting

Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients

NCT06615635Not ApplicableNot Yet Recruiting

Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients

NCT05074433Phase 3TerminatedPrimary

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

NCT07120464Recruiting

Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations

NCT03168815Not ApplicableActive Not RecruitingPrimary

Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy

NCT03808922Phase 3Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT06610643Not ApplicableNot Yet Recruiting

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

NCT05020145CompletedPrimary

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

NCT05545319Phase 2Withdrawn

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT03262584Completed

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT02057289Phase 1TerminatedPrimary

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

NCT01069601Phase 2TerminatedPrimary

H1N1sw Vaccine in Adult Transplant Recipients

NCT01258023Phase 2CompletedPrimary

Seasonal Flu Vaccine in Adult Transplant Recipients

NCT01301755UnknownPrimary

Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration

Showing all 15 trials

Research Network

Activity Timeline